| _version_ | 1866902266388152320 |
|---|---|
| author | Dr Sunil Santhosh |
| author_facet | Dr Sunil Santhosh |
| contents | <div> <table> <tbody> <tr> <td style="padding: 0in 9.0pt 0in 9.0pt;"> <p><strong><span>Introduction: </span></strong><span>The risk of postoperative venous thromboembolism (VTE) is higher for patients having total knee arthroplasty (TKA) or total hip arthroplasty (THA).One of the main causes of post-operative morbidity and mortality is VTE, which includes both pulmonary embolism (PE) and deep vein thrombosis (DVT). Up to 40–60% of post-operative patients may develop DVT and 1-2 percent may die from PE, if proper prophylaxis is not take.According to current standards, prophylactic treatment should be administered for at least 10–14 days and should be seriously considered for up to 35 days</span></p> <p><strong><span>Objectives of study: </span></strong><span>To compare the effect of Ecospirin and Rivoroxan<span> </span>in prevention of DVT in post TKR patients </span></p> <p><strong><span>Materials and methods: </span></strong><span>Patient who underwent TKR<span> </span>in BGSGIMS<span> </span>during a period of 2 yrs ( from December 2022 – December 2024 ) were given Ecospirin/ Rivaroxaban pre and post<span> </span>operativly were observed for the signs of DVT for a given period<span> </span>and compared the effects of both drugs during the period </span></p> <p><strong><span>Results: </span></strong><span>This is a hospital-based study. The trial duration was two years, from December 2022 to December 2024.The study comprised a total of 30 patients. Of these, 20 were females and 10 were males. Out of 30 patients no one developed VTE or PE . There was no significant difference in incidance of<span> </span>PE and VTE between ecospirin and rivoroxaban groups</span></p> <p><strong><span>Conclusion: </span></strong><span>In our study out of 30 patients 18 patients were given ecospirin and 12 were given rivoroxaban . Pre operatevly and post operatevily assesed using Knee society score. Effect of ecosipirin and rivoroxaban is analysed. There is no statistically difference in incidance of DVT and PE . The limitations of our study includes it is a hospital based study , only limited patients are assessed and it doesn’t conclude the whole population</span></p> </td> </tr> </tbody> </table> </div> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_16789968 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Prospective comparitive study between Ecospirin and Rivoraxaban in prevention of DVT in post TKR patients Dr Sunil Santhosh <div> <table> <tbody> <tr> <td style="padding: 0in 9.0pt 0in 9.0pt;"> <p><strong><span>Introduction: </span></strong><span>The risk of postoperative venous thromboembolism (VTE) is higher for patients having total knee arthroplasty (TKA) or total hip arthroplasty (THA).One of the main causes of post-operative morbidity and mortality is VTE, which includes both pulmonary embolism (PE) and deep vein thrombosis (DVT). Up to 40–60% of post-operative patients may develop DVT and 1-2 percent may die from PE, if proper prophylaxis is not take.According to current standards, prophylactic treatment should be administered for at least 10–14 days and should be seriously considered for up to 35 days</span></p> <p><strong><span>Objectives of study: </span></strong><span>To compare the effect of Ecospirin and Rivoroxan<span> </span>in prevention of DVT in post TKR patients </span></p> <p><strong><span>Materials and methods: </span></strong><span>Patient who underwent TKR<span> </span>in BGSGIMS<span> </span>during a period of 2 yrs ( from December 2022 – December 2024 ) were given Ecospirin/ Rivaroxaban pre and post<span> </span>operativly were observed for the signs of DVT for a given period<span> </span>and compared the effects of both drugs during the period </span></p> <p><strong><span>Results: </span></strong><span>This is a hospital-based study. The trial duration was two years, from December 2022 to December 2024.The study comprised a total of 30 patients. Of these, 20 were females and 10 were males. Out of 30 patients no one developed VTE or PE . There was no significant difference in incidance of<span> </span>PE and VTE between ecospirin and rivoroxaban groups</span></p> <p><strong><span>Conclusion: </span></strong><span>In our study out of 30 patients 18 patients were given ecospirin and 12 were given rivoroxaban . Pre operatevly and post operatevily assesed using Knee society score. Effect of ecosipirin and rivoroxaban is analysed. There is no statistically difference in incidance of DVT and PE . The limitations of our study includes it is a hospital based study , only limited patients are assessed and it doesn’t conclude the whole population</span></p> </td> </tr> </tbody> </table> </div> |
| title | Prospective comparitive study between Ecospirin and Rivoraxaban in prevention of DVT in post TKR patients |
| url | https://doi.org/10.5281/zenodo.16789968 |